DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Demcizumab
Demcizumab
Clinical Protocol
Precision Medicine for Human Cancers with Notch Signaling Dysregulation (Review)
The Role of Cancer Stem Cells in Colorectal Cancer: from the Basics to Novel Clinical Trials
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
PD-1 / PD-L1 Combination Therapies
Research Ethics Committee Reference Number
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Understanding and Targeting Resistance to Anti-Angiogenic Therapies
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Double Trouble Sinks Oncomed As Investors Look to Earlier Assets
Phase 1B Study of Demcizumab Plus Pemetrexed and Carboplatin In
AHRQ Healthcare Horizon Scanning System – Status Update Horizon
A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
Adis R&D Insight
Oncompass Report NÉV Anonymous a Realtime Oncology Molecular Treatment Calculator Számításaival
New Horizons in Tumor Microenvironment Biology: Challenges and Opportunities Chen Et Al
Top View
Stembook 2018.Pdf
The Combination of Gemcitabine/Nab-Paclitaxel with An
Ovarian Cancer Stem Cells and Targeted Therapy
Targeting Cancer Stem Cells
(INN) for Biological and Biotechnological Substances
Signalling Pathways Regulating Organ-Specific Endothelial
Tumor Microenvironment and Targeted Therapies
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Orphan Drug Designation List
A Phase I First-In-Human Study of Enoticumab (REGN421), a Fully-Human Delta-Like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Riport Letöltése
Presentation Title
A Phase 1B Study of Demcizumab Plus Pemetrexed and Carboplatin in Patients with 1St Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Celgene's Multibillion Spree on Oncomed/NYC
(2006.01) C07d 413/14
A Ph1b Study of Demcizumab (DEM, Anti-DLL4) with Gemcitabine (GEM) in Patients with 1St Line Locally Advanced Or Metastatic Pancreatic Cancer
( 12 ) Patent Application Publication
Oncology Drugs in the Pipeline
Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies
Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
Top Notch Targeting Strategies in Cancer: a Detailed Overview of Recent Insights and Current Perspectives
Oncompass Report NÉV Anonymous a Realtime Oncology Molecular Treatment Calculator Számításaival
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
Anti-Angiogenic Alternatives to VEGF Blockade Khan, Kabir A; Bicknell, Roy
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Anti-Angiogenic Alternatives to VEGF Blockade
(INN) for Biological and Biotechnological Substances
A Phase I First-In-Human Study of Enoticumab
Antonio Cubillo Gracian, MD., Ph.D. (Aug 1St, 1970) BIOSKETCH: 1. EDUCATION
Integrative Gastroenterology and Hepatology Immunotherapy and Pancreatic Cancer Allen T*, Shoja G and Court NB
Targeting Human Cancer Stem Cells with Monoclonal Antibodies
Study Protocol and Informed Consent Form
Has Approved Aloxi® (Palonosetron HCI) Cyramza™ (Ramucirumab)For
Phase 1 Dose Escalation Study of Demcizumab Title
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
(12) 按照专利合作条约所公布的国际申请w O 2016/050208
Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses
ONCOMPASS Report Provides Information Published in the Scientific Literature Associated with the Molecular Profile of the Tumor
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT